Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.

Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Quantimetrix Dipper POCT now with integrated barcode

May 2024—Quantimetrix announced that its Dipper POCT urinalysis dipstick control pouches now include a barcode. The integrated barcode is designed to streamline the workflow and reduce errors that can arise from manually entering lot numbers and expiration dates. Dipper POCT kits contain ready-to-use, single-use plastic pouches in two levels, each filled with 1.5 mL of liquid control material. The product is stable for three months at room temperature and up to three years at 2º to 8ºC.

FDA clears Pathfast POC hs-cTnI test

May 2024—Polymedco announced FDA 510(k) clearance of the Pathfast hs-cTnI-II, a high-sensitivity cardiac troponin assay for the diagnosis of myocardial infarction at the point of care. The test delivers results in 17 minutes on the Pathfast Biomarker analyzer using whole blood and plasma samples.

PixCell adds distribution partners in the U.S.

May 2024—PixCell Medical announced a strategic distribution partnership with Medline, Henry Schein, and Thermo Fisher Scientific to increase accessibility to its flagship product, the HemoScreen point-of-care, five-part differential CBC analyzer, in the United States. The FDA-cleared analyzer can be used with capillary or venous anticoagulated whole blood and provides results in five minutes.

Bruker to acquire NanoString for $392.6 million

May 2025—NanoString Technologies announced that substantially all of its assets will be acquired by Bruker Corp. for approximately $392.6 million in cash consideration, plus the assumption of certain liabilities. The transaction was agreed to under a court-supervised Chapter 11 sale process and is expected to close in early May.

FDA grants de novo classification for plasma cell enrichment kit

May 2024—Stemcell Technologies announced that the FDA has granted de novo classification for its immunomagnetic plasma cell enrichment kit. The EasySep Human Bone Marrow CD138 Positive Selection kit, for in vitro diagnostic applications, is intended to enrich CD138 positive plasma cells from bone marrow samples collected from patients with multiple myeloma, as part of a preanalytical workflow. Commercial launch of the kit is planned in the European Union, Canada, the United Kingdom, and the United States.

Bosch, Randox invest €150 million in Vivalytic platform

May 2024—Bosch and Randox Laboratories have entered into a strategic partnership in which the two companies will invest around €150 million in joint research, development, and distribution for new tests for Bosch’s Vivalytic platform. One goal of the partnership is to develop an in vitro diagnostic multiplex sepsis test for the Vivalytic analyzer. It will be the first test to feature Bosch’s novel BioMEMS technology.

Labcorp wins bid for select assets of Invitae

May 2024—Labcorp announced it will purchase select assets of genetics company Invitae for $239 million. The company expects the transaction to generate about $275 to $300 million in annual revenue, with the majority in specialty testing areas such as oncology and rare diseases. Through the transaction, which requires court approval pending a hearing scheduled on May 6, Labcorp will acquire assets being auctioned through a voluntary bankruptcy protection process. The transaction is expected to close in the third quarter of this year.

FDA approves OncoReveal CDx on Illumina MiSeq Dx system

May 2024—Pillar Biosciences announced that the FDA has approved the company’s premarket approval supplement application for its OncoReveal CDx pan-cancer solid tumor in vitro diagnostic assay. The panel covers 22 clinically relevant genes in one multiplex reaction and has a fully automatable workflow with a sample-to-report time of as little as 48 hours. Up to 46 clinical samples can be batched on a single MiSeq Dx run.

Abbott TBI cartridge cleared for use with whole blood

May 2024—Abbott’s i-Stat TBI cartridge has received FDA clearance for use with whole blood, allowing clinicians to help assess patients with suspected concussion at the patient’s bedside. The test measures ubiquitin C-terminal hydrolase L1 and glial fibrillary acidic protein to help evaluate patients 18 years of age and older up to 24 hours after injury. Results are available in 15 minutes on the portable i-Stat Alinity system.

Bio-Rad expands availability of Unity Next Peer QC

May 2024—Bio-Rad Laboratories has launched its Unity Next Peer QC data management software in Europe, the Middle East, and Africa. The software is designed to help troubleshoot quality control failures and increase confidence in patient testing results and offers on-demand access to peer reporting and quality control data. Labs new to Bio-Rad’s suite of QC data management products can get guided support and training from the company.

MARKETPLACE

TRENDING